Combination of Intravitreal Ranibizumab With or Without Macular Laser Photocoagulation for ME Secondary to BRVO

Sponsor
Beijing Hospital
Study ID
NCT03054766
Status
Completed

Conditions

  • Branch Retinal Vein Occlusion
  • Laser Photocoagulation
  • Ranibizumab

Eligibility Criteria

Sex
ALL
Age
18 Years - 90 Years
Healthy Volunteers
Not accepted

Interventions

  • Ranibizumab combined macular laser — PROCEDURE
    subjects in one group receive both macular laser photocoagulation and ranibizumab injections but ones in the other group just received ranibizumab injection.
  • Ranibizumab — DRUG
    all subjections received 3+PRN ranibizumab injections by BCVA stabilization

Study Details

To investigate the efficacy of laser photocoagulation combined with ranibizumab intravitreal injection in macular edema (ME) secondary to branch retinal vein occlusion (BRVO) in long term.

Key Dates

First listed
Feb 16, 2017
Start date
Feb 14, 2017
Status verified
Dec 2022
Primary completion
Feb 1, 2018
Completion
Jan 28, 2019

Study Design

Enrollment
80 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Ranibizumab only
    Sham macular laser photocoagulation treatment after third ranibizumab injection with PRN intravitreal injections of ranibizumab 0.5 mg guided by BCVA stabilization Interventions :Ranibizumab injection Interventions :Sham macular laser
  • Experimental: Ranibizumab combined macular laser
    Macular laser photocoagulation treatment after third ranibizumab injection with PRN intravitreal injections of ranibizumab 0.5 mg guided by BCVA stabilization Interventions :Ranibizumab injection Interventions :Macular laser photocoagulation

Primary Outcome Measure

visual acuity changes [ Time Frame: one year ]